mycophenolate mofetil FDA Alerts
The FDA Alert(s) below may be specifically about mycophenolate mofetil or relate to a group or class of drugs which include mycophenolate mofetil.
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.
Recent FDA Alert(s) for mycophenolate mofetil
Par Pharmaceutical, Inc. Issues Voluntary Nationwide Recall of One Lot of Mycophenolate Mofetil for Injection, USP Due to the Presence of a Glass Fragment Observed in One Vial of Reconstituted Product
May 3, 2019
Audience: Consumer, Health Professional, Pharmacy
Endo International plc, announced today that one of its operating companies, Par Pharmaceutical, Inc., is voluntarily recalling one lot of Mycophenolate Mofetil for Injection, USP to the hospital and retail pharmacy level. One vial of product was observed containing a glass fragment after reconstitution.
The administration of a glass particulate, if present in an intravenous drug, may result in local irritation or swelling in response to the foreign material. More serious potential outcomes would include blockage and clotting in blood vessels, which may be life-threatening. To date, Par Pharmaceutical, Inc. has not received any reports of adverse events related to this recall.
Mycophenolate Mofetil for Injection, USP is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate Mofetil for Injection, USP should be used concomitantly with cyclosporine and corticosteroids. The affected Mycophenolate Mofetil for Injection, USP includes lot AD812, expiry 09/2020. The product, manufactured for Par Pharmaceutical, Inc. by Gland Pharma Limited, is packaged in cartons of 4 single use vials with NDC 42023-172-04. Mycophenolate Mofetil for Injection, USP, lot AD812 was distributed nationwide in the U.S. to wholesale distribution locations between January 23, 2019, and February 11, 2019.
Vials from the affected lot bear this label:
Par Pharmaceutical, Inc. is providing written notification to national wholesale accounts and direct customer locations that have received the affected lot and is arranging for return of all recalled product through Inmar, Inc. Wholesale distributors, retail pharmacies, and hospital pharmacies that have the product being recalled should immediately stop further distribution and use of vials from Lot AD812 and return any unused product by following the instructions below:
- Please contact Inmar, Inc. either by phone at 1-800-967-5952, extension 1 (Monday through Friday between 9 am and 5 pm ET), or by email at firstname.lastname@example.org to obtain return authorization labels and return shipping instructions.
- Upon contacting Inmar, Inc. please be prepared to provide proof of purchase to receive reimbursement for returned product.
Wholesalers, retailers, pharmacies, and consumers with questions regarding this recall can contact Inmar, Inc. either by phone at 1-800-967-5952, extension 1 (Monday through Friday between 9 am to 5 pm ET), or by email at email@example.com. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
- Complete and submit the report Online
- Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Immunosuppressant Drugs: Required Labeling Changes
Jul 14, 2009
Audience: Transplant and nephrology healthcare professionals
Sirolimus (marketed as Rapamune), Cyclosporine (marketed as Sandimmune and generics), Cyclosporine modified (marketed as Neoral and generics), Mycophenolate mofetil (marketed as Cellcept and generics), Mycophenolic acid (marketed as Myfortic)
The FDA is requiring the makers of certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at increased risk for opportunistic infections, such as activation of latent viral infections, including BK virus-associated nephropathy. These immunosuppressant drugs are used to protect against the rejection of certain organ transplants. The association of BK virus-associated nephropathy has previously been reported for another immunosuppressant drug, tacrolimus (marketed as Prograf). Monitoring for this serious risk and early intervention by the health care provider is critical. Adjustments in immunosuppression therapy should be considered for patients who develop BK virus-associated nephropathy.
FDA is continuing to review the safety of immunosuppressant drug products used in renal transplantation. The FDA urges both healthcare professionals and patients to report side effects from the use of immunosuppressant drug products to the FDA's MedWatch Adverse Event Reporting program.
[07/14/2009 - Information for Healthcare Professionals - FDA]
CellCept (mycophenolate mofetil), Myfortic (mycophenolate acid)
Apr 10, 2008
Audience: Transplantation specialists, infectious disease specialists, other healthcare professionals[Posted 04/10/2008] FDA informed healthcare professionals that the Agency is investigating a potential association between the use of CellCept and Myfortic, medicines used to prevent organ rejection, and the development of progressive multifocal leukoencephalopathy (PML), a life-threatening disease. PML is a rare disorder that affects the central nervous system usually occurring in patients with immune systems suppressed by disease or medicines. FDA is reviewing data submitted by Roche, including postmarketing reports it has received of PML in patients who took CellCept or Myfortic, and the proposed revisions to the CellCept prescribing information. FDA has asked Novartis, the maker of Myfortic, for data on PML cases and to revise the Myfortic prescribing information to include the same information about PML included in the CellCept prescribing information. FDA anticipates it may take about 2 months to complete its review of the postmarketing reports and the proposed revisions to the prescribing information. As soon as the review is completed, FDA will communicate the conclusions and recommendations to the public.
Until further information is available, patients and healthcare professionals should be aware of the possibility of PML, such as localized neurologic signs and symptoms in the setting of a suppressed immune system, including during therapy with CellCept and Myfortic.
[April 10, 2008 - Communication About an Ongoing Safety Review - FDA]
More mycophenolate mofetil Resources
- Mycophenolate mofetil oral/injection Consumer Information
- Mycophenolate Mofetil Tablets Consumer Information
- Mycophenolate Mofetil Capsules Consumer Information
- Mycophenolate Mofetil Injection Solution Consumer Information
- Mycophenolate Mofetil Oral Suspension Consumer Information
- Mycophenolate Intravenous Advanced Consumer Information
- Mycophenolate mofetil Advanced Consumer Information
- Mycophenolate AHFS DI Monograph
- Mycophenolate Prescribing Information
- Mycophenolate Mofetil Prescribing Information
- Mycophenolate Mofetil Injection Prescribing Information
- Mycophenolate Suspension Prescribing Information
- Mycophenolate Tablets Prescribing Information
- Mycophenolate A-Z Drug Facts